On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of ...

Mark Pappas, who founded popular seafood restaurants including the iconic Pappas Restaurant & Sports Bar, died Sunday at 93.

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

A pill version of Novo Nordisk’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of high-risk studies that aimed to open up a new use for blockbuster obesity drugs. Patients ...

Chris Hemsworth's touching road trip with his father Craig, who has "early-stage Alzheimer's," is chronicled in a National ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Shares of Novo Nordisk ( NVO 5.58%) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

Arginine reduced amyloid beta aggregation in vitro and in both Drosophila and AppNL-G-F mouse models of Alzheimer’s disease, ...

Choose a calm moment, listen first and give the person time to share how they feel. Here are some other tips on how to help a ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

There’s rarely good news about Alzheimer’s disease, but a failed study may open the door to more research about vascular ...